Clinical Application of Glucagon-Like Peptide-1 Receptor Agonists.
10.4093/jkd.2015.16.4.252
- Author:
Se Hee MIN
1
;
Young Min CHO
Author Information
1. Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea. ymchomd@snu.ac.kr
- Publication Type:Review
- Keywords:
Glucagon-like peptide 1;
Obesity;
Type 2 diabetes mellitus
- MeSH:
Absorption;
Appetite;
Deceleration;
Diabetes Mellitus, Type 2;
Gastric Emptying;
Glucagon-Like Peptide 1*;
Humans;
Hypoglycemia;
Incretins;
Insulin;
Obesity;
Pharmacokinetics;
Weight Gain;
Glucagon-Like Peptide-1 Receptor
- From:Journal of Korean Diabetes
2015;16(4):252-259
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Glucagon-like peptide 1 (GLP-1) is an incretin hormone that is released from enteroendocrine L-cells upon nutrient absorption; it stimulates glucose-dependent insulin secretion from pancreatic betacells. GLP-1 has pleiotropic effects including deceleration of gastric emptying, decreased appetite, and increased satiety. Treatment with GLP-1 receptor agonists (GLP-1RAs) improves glycemic control in patients with type 2 diabetes without increasing the risk of hypoglycemia or weight gain. Current GLP-1RAs can be classified by their structure (exendin-4-based or human GLP-1-based), duration of action, and molecular size. Different GLP-1RAs exhibit different pharmacokinetics and pharmacodynamics. Herein we review the characteristics of available GLP-1RAs and discuss current issues such as insulin combination therapy and anti-obesity effects.
